operations - the business of human optimization

Optimi^TM Products for an Optimized Lifestyle

Optimi Health’s highly sought-after range of fungi varieties includes Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. Our popular and proven varieties aim to deliver a lineup of uniquely Canadian propietary nutraceutical products aimed at kickstarting optimal human perfomance.

Optimi Health is positioning itself to meet the needs of the rapidly expanding health & wellness sector and to serve consumers looking to prioritize personal opimization through consumption of high quality, natural plant-based products.

OUR NUTRACEUTICALS MISSION:

Optimi believes that being in both the functional mushroom growth and health food industry provides it with an advantage over its competitors, which are largely either solely involved with farming mushrooms or producing wellness products.

The Company has targeted a commercial advantage by growing its own mushrooms for its health food products which will ultimately serve to reduce the need for intermediaries. The Company aims to fully control the purity of its products throughout the entire process of growth, extraction, and consumer sales.

ONLINE SALES

Optimi plans to distribute its products in Canada through its e-commerce website platform in Q3, 2021.

See below for a description of each functional mushroom variety and related product.

Longevity Mushroom Extract

The Longevity capsules are here to repair and recharge. Known as the “Queen of mushrooms” and “mushroom of immortality,” Reishi has been used for over 2,000 years by eastern societies to help promote longevity and wellbeing.

Mushroom ingredients

Limitless Vegan Protein

Designed for maximum human optimization, we’ve combined our proprietary blend of five functional mushrooms with a delicious vegan protein powder. This perfect stack of nutrition and functional mushrooms will keep you fueled and thriving. We created the Optimi Vegan Protein Formulation with your betterment and peak performance in mind.

Mushrooms ingredients

Optimi Formulation Capsules

Meet your daily mushroom complex. A proprietary blend of 5 functional mushrooms formulated to optimize your day-to-day performance. We created the Optimi Formulation with your betterment and peak performance in mind.

Mushrooms ingredients

IMMUNITY MUSHROOM EXTRACT

Turkey Tail is one of the most commonly found mushrooms in the world. Yet, its incredible benefits put this mushroom in a league of its own.

Mushroom ingredients

Defense Mushroom Extract

The Defense capsules are your protector and fighter. Chaga is often called the king of medicinal fungi and has been used as a medicinal fungus in Asia for thousands of years.

Mushrooms ingredients

PERFORM MUSHROOM EXTRACT

Wild cordyceps is a parasitic fungus that use insects as a host to flourish. The Perform capsules are here to replenish and provide antioxidant and immune support.

Mushrooms ingredients

Mindful Mushroom Extract

Lion’s Mane is used by high performance individuals looking to get an edge.

Mushroom ingredients

Coming Soon

White label services are available for the creation of off-brand products.

Coming Soon

White label services are available for the creation of off-brand products.

Optimi^TM Farms

In July of 2020, Optimi Farms entered an agreement to lease and build two GMP-capable 10,000 sq ft. purpose-built cultivation and processing facilities in Princeton, BC. These facilities will be used to grow, process, research & develop functional and future mushroom products. Optimi projected an overall facility budget of $8.2 million to completion. The building shells have been erected and installation of interior processing facilities, including state-of-the-art machinery and processing equipment commenced in January of 2021, with completion anticipated by the end of Q2, 2021.

OPTIMI FARMS MISSION:

Deliver best in the world GMP certified production of natural functional and psilocybin fungi varieties.

FACILITY ONE: OPTIMI FUNCTIONAL

Optimi Farms Facility #1 is focused on growing high demand functional mushroom varieties such as Lion’s Mane, Reishi, Turkey Tail and Cordyceps.

Operational Considerations:

Rapid path for sales of Canadian grown functional mushrooms.
Efficient design configuration & multiple dedicated areas for maximum yield.
Integrated environmental controls and cultivation systems (Argus Controls).
Multiple climate-controlled rooms allow for a variety of strains and reduces contamination risk (GMP).
No extraction mark-up or loss in wholesale margin from co-packers using Optimi functional mushroom growth formulas and methods.

FACILITY TWO: OPTIMI DEVELOPMENTAL

Optimi Farms Facility #2 is designed to accommodate either functional mushroom or pharmaceutical grade production (GMP) of functional or psychoactive mushrooms (i.e. containing psilocybin), and is intended to service both large scale medicinal, and potential wellness market opportunities.

Operational Considerations:

Health Canada research exemption license has been approved and a dealer’s license is pending. This paves the way to pilot cultivation, advanced research and development, control studies, peer review registry and a significant competitive timeline advantage towards pharmaceutical industry applications.
Onsite product cultivation, extraction, testing, fulfilment, shipping, distribution, and sales.
Opportunity to supply Health Canada certified research programs, clinical trials & academic studies.
Pre-existing cannabis connections to Europe, and partnerships established in Canada for medicinal purposes through a contractual agreement with BC Green Pharmaceuticals.
Infrastructure in-place to capitalize on the increasing regulatory acceptance of psilocybin.

Optimi^TM Labs

Our in-house facility is designed to accelerate agricultural innovation, advanced agronomy, and improved efficiencies in production and product development.

Through strategic partnerships with academic institutions, professional researchers and scientific leaders, Optimi Labs intends to add value through intellectual property development, specialty formulations, growth optimization and studies on enhanced physical and mental performance development.

OPTIMI LABS MISSION:

Leading, testing, and participating in research and clinical studies that identify proprietary solutions that help solve human disease and optimize human potential.

Optimi^TM Labs Key Functions

Optimize commercial cultivation processes
Improve strain quality & yield
Improve extraction efficiencies
Fungi extract innovation
Product development
Innovation in human delivery mechanisms
Synthetic and non-synthetic compound exploration
Active compound investigation
Pharmaceutical development & new drug formulation research

Optimi Labs is developing an intellectual property (IP) strategy encompassing delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new formulations, testing and protocol regimens specific to mushroom based products. To expedite innovation, Optimi Labs works with both academic and strategic development partnerships.

Our initial focus is on the research and development of functional mushrooms (non-psychedelic) cultivation and extraction, then advancing into research into mushroom-derived psilocin/psilocybin which is designed to investigate the treatment of mental illness, addiction, and other health conditions if and as permitted by applicable laws, pursuant to the Research Exemption and/or Dealer’s License.

To accelerate our research prior to the receipt of the Dealer’s License, Optimi aims to commission a number of research and development projects related to psychedelic compounds. To this end, Optimi entered into an agreement with Numinus Wellness Inc. to provide certain psychedelic research, development and testing services. Numinus holds a Health Canada Dealer’s License and all activities proposed under the Company’s arrangement with Numinus will be carried out by Numinus personnel at its facility in compliance with its Dealer’s License requirements. All resulting Intellectual Property (IP) to be owned 100% by Optimi.

The Future of Mushrooms: In order to include psychedelic products in the Company’s extended research activities, the Company has received a Research Exemption and has applied for a Dealer’s License from Health Canada.

Clinical Trials – Academic Consultants

The Company has also entered into a Master Consulting Agreement (“MCA”) with UTI Limited Partnership (“Innovate Calgary”), the innovation transfer and business incubator centre for the University of Calgary. Innovate Calgary is an incubator designed to provide consulting services that assists ventures in the life sciences or biomedical industries with: (a) reviewing, designing, planning and/or conducting clinical trial studies, (b) presenting data generated from clinical trial studies, and/or (c) seeking clinical trial-related services from third parties. Under the MCA and first Statement of Work, Innovate Calgary will design and carry out a clinical trial in respect of the potential health and wellness applications of the Company’s products and proposed products, expected to be completed within one year.

Development Opportunity – Psilocybin

Scientific interest in classic psychedelics, such as psilocybin, has returned and grown because of several promising studies, validating earlier research. For mood and anxiety disorders, three controlled trials have suggested that psilocybin may decrease symptoms of depression and anxiety in the context of cancer-related psychiatric distress for at least 6 months following a single acute administration. A small, open-label study in patients with treatment resistant depression showed reductions in depression and anxiety symptoms three months after two acute doses. For addiction, small, open-label pilot studies have shown promising success rates for both tobacco and alcohol addiction. Safety data from these various trials, which involve careful screening, preparation, monitoring, and follow-up, indicate the absence of severe drug-related adverse reactions (Source: Johnson & Griffiths, 2017). Based on a recent report by Data Bridge Market Research, Market Analysis Study, 2020, the psychedelic drug market is growing with a compound annual growth rate of 16.3% and expected to reach USD 6,859.95 million by 2027.

Optimi’s goal is to become strategically positioned as a producer and distributor of medical psilocybin and other psychedelic/nutraceutical products, where permitted by applicable laws.

CSE: OPTI | OTC: OPTHF | FRA: 8BN

operations - the business of human optimization